Timely access to high-quality peptides is essential in drug discovery, especially for screening, structure-activity relationship (SAR) studies, and early-stage preclinical research. Any delay in ...
Sunil Shah, CEO of O2h said “We are excited to be a part of and support the research programs that Novacta is pioneering in the area of Lantibiotics and Bacteriocins. The large investment that they ...